David Michelson

David Michelson, M.D., is the Consulting Chief Medical Officer of Regenacy. Prior to joining Regenacy he was the Chief Medical Officer at Proclara Biosciences, and before that was the Neuroscience Therapeutic Area Head and Vice President for Clinical Development at Merck. He began his career in drug development at Lilly, where he held multiple roles in early and late phase drug development. David received his M.D. from the Albert Einstein College of Medicine in New York, and completed his residency in psychiatry at Yale University, where he also served as a chief resident and faculty member prior to joining the National Institute of Mental Health as a research physician. David has authored more than 100 papers, and has led multiple successful drug development programs in the US and globally.